Choose your language

English

English

Home
Products
Specialties
Services
Contact Janssen

Choose your language

English

EN

English

EN

Darzalex-news-1

‌

Categories / tags

Related media

Darzalex is the first approved CD38-targeting immunotherapy for multiple myeloma (MM)

Learn more about the mode of action

Darzalex is the first approved CD38-targeting immunotherapy for multiple myeloma (MM)

Learn more about the mode of action

© Janssen-Cilag NV 2021. This site is published by Janssen-Cilag NV which is solely responsible for its content. It is intended for Healthcare professionals in Belgium and Luxembourg.

Privacy Policy Legal Notice Cookie Policy

Cookie Settings